18 October 2020>: Clinical Research
Expression of Matrix Metalloproteinase-2, Matrix Metalloproteinase-9, Tissue Inhibitor of Metalloproteinase-1, and Changes in Alveolar Septa in Patients with Chronic Obstructive Pulmonary Disease
Yongxiang Zhang ABCDE , Yuechuan Li AEFG* , Zhen Ye BD , Hui Ma CFDOI: 10.12659/MSM.925278
Med Sci Monit 2020; 26:e925278
Table 6 Comparison of expression of MMP-2, MMP-9 and TIMP-1 in alveolar septa between COPD group and control group.
Groups | Control (n=20) | COPD | |||
---|---|---|---|---|---|
Total (n=40) | Mild (n=8) | Moderate (n=24) | Severe (n=8) | ||
MMP-2 | 0.11±0.02 | 0.15±0.04** | 0.13±0.02** | 0.16±0.02,** | 0.22±0.06,** |
MMP-9 | 0.11±0.02 | 0.15±0.03** | 0.122±0.03 | 0.16±0.02,** | 0.19±0.02,** |
TIMP-1 | 0.11±0.03 | 0.14±0.06** | 0.10±0.03 | 0.13±0.03* | 0.24±0.05,,** |
MMP-2/TIMP-1 | 1.05±0.24 | 1.10±0.26 | 1.15±0.32 | 1.03±0.16 | 0.91±0.37* |
MMP-9/TIMP-1 | 1.08±0.41 | 1.17±0.37 | 1.08±0.41 | 1.31±0.31* | 0.85±0.33,,* |
COPD – chronic obstructive pulmonary disease; DLCO – carbon monoxide diffusing capacity; MMP – matrix metalloproteinase, TIMP-1 – tissue inhibitor of metalloproteinase-1; Control group, * ** # ## & && |